Pancreatic Cancer Research

ResearcherUniversity of MichiganNo recent work listed

Ramesh K. Ramanathan

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5113733729. Sources: ClinicalTrials.gov.

Their work

Papers
33 (first author 10, last author 1)
Trials
2 (principal investigator on 2)
Grants
0
Labs led
0
Collaborators
118
Papers, trials and grants by year

2011: 3 papers, 1 trial · 2012: 2 papers · 2013: 4 papers · 2014: 4 papers · 2015: 2 papers · 2016: 4 papers, 1 trial · 2017: 7 papers · 2018: 2 papers · 2019: 2 papers · 2020: 3 papers

Papers 33

  1. Response Rate Following Albumin-Bound Paclitaxel Plus Gemcitabine Plus Cisplatin Treatment Among Patients With Advanced Pancreatic Cancer: A Phase 1b/2 Pilot C… Co-author DOI 10.1001/jamaoncol.2019.3394↗
  2. Phase 2 study of vismodegib, a hedgehog inhibitor, combined with gemcitabine and nab-paclitaxel in patients with untreated metastatic pancreatic adenocarcinoma. Co-author DOI 10.1038/s41416-019-0683-3↗
  3. Nomogram for Estimating Overall Survival in Patients With Metastatic Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000001563↗
  4. A Phase 2 Study of PCI-27483, a Factor VIIa Inhibitor in Combination with Gemcitabine for Advanced Pancreatic Cancer. Co-author DOI 10.1159/000495988↗
  5. Phase IB/II Randomized Study of FOLFIRINOX Plus Pegylated Recombinant Human Hyaluronidase Versus FOLFIRINOX Alone in Patients With Metastatic Pancreatic Adenoc… Co-author DOI 10.1200/jco.18.01295↗
  6. Metastatic Pancreatic Cancer: ASCO Clinical Practice Guideline Update. Co-author DOI 10.1200/jco.2018.78.9636↗
  7. Emerging Therapies and Future Directions in Targeting the Tumor Stroma and Immune System in the Treatment of Pancreatic Adenocarcinoma. First author DOI 10.3390/cancers10060193↗
  8. Second-line treatment in patients with pancreatic ductal adenocarcinoma: A meta-analysis. Co-author DOI 10.1002/cncr.30927↗
  9. Clinical study of genomic drivers in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/bjc.2017.209↗
  10. Tumor Reduction in Primary and Metastatic Pancreatic Cancer Lesions With nab-Paclitaxel and Gemcitabine: An Exploratory Analysis From a Phase 3 Study. First author DOI 10.1097/mpa.0000000000000742↗
  11. Immunotherapy in pancreatic cancer treatment: a new frontier. Co-author DOI 10.1177/1756283x16667909↗
  12. 18F-FDG PET/CT response in a phase 1/2 trial of nab-paclitaxel plus gemcitabine for advanced pancreatic cancer. Last author DOI 10.1186/s40644-017-0125-5↗
  13. Targeting the stroma in pancreatic cancer. First author DOI 10.21037/cco.2017.11.02↗
  14. A phase 2 trial of personalized cytotoxic therapy based on tumor immunohistochemistry in previously treated metastatic pancreatic cancer patients. Co-author DOI 10.21037/jgo.2017.09.05↗
  15. CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitab… Co-author DOI 10.1093/annonc/mdw006↗
  16. Positron emission tomography (PET) as a predictive measure in patients with metastatic pancreatic cancer and normal CA19-9 levels at baseline. Co-author DOI 10.1093/annonc/mdw177↗
  17. Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. Co-author DOI 10.1200/jco.2016.67.1412↗
  18. Dose modification and efficacy of nab-paclitaxel plus gemcitabine vs. gemcitabine for patients with metastatic pancreatic cancer: phase III MPACT trial. First author DOI 10.21037/jgo.2016.01.03↗
  19. (90)Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancreatic cancer after two or more prior ther… First author DOI 10.1016/j.ejca.2015.06.119↗
  20. Prognostic factors of survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with meta… Co-author DOI 10.1634/theoncologist.2014-0394↗
  21. Dual blockade of epidermal growth factor receptor and insulin-like growth factor receptor-1 signaling in metastatic pancreatic cancer: phase Ib and randomized … Co-author DOI 10.1002/cncr.28744↗
  22. Pancreatic adenocarcinoma: treating a systemic disease with systemic therapy. Co-author DOI 10.1093/jnci/dju011↗
  23. Disseminated intravascular coagulation secondary to advanced pancreatic cancer treated successfully with combination chemotherapy. First author DOI 10.1159/000365552↗
  24. STAG2 is a clinically relevant tumor suppressor in pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/gm526↗
  25. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. Co-author DOI 10.1056/nejmoa1304369↗
  26. Phase I trial of AEG35156 an antisense oligonucleotide to XIAP plus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma. Co-author DOI 10.1097/coc.0b013e3182467a13↗
  27. Phase II study of induction fixed-dose rate gemcitabine and bevacizumab followed by 30 Gy radiotherapy as preoperative treatment for potentially resectable pan… First author DOI 10.1245/s10434-013-3161-9↗
  28. Current and emerging treatment options in pancreatic cancer. Co-author PMID 24518425↗
  29. A randomized phase II of gemcitabine and sorafenib versus sorafenib alone in patients with metastatic pancreatic cancer. First author DOI 10.1007/s10637-011-9658-9↗
  30. Genome-wide characterization of pancreatic adenocarcinoma patients using next generation sequencing. Co-author DOI 10.1371/journal.pone.0043192↗
  31. Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. Co-author DOI 10.1200/jco.2011.34.8904↗
  32. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. First author DOI 10.1200/jco.2011.36.5742↗
  33. Phase II study of gemcitabine and erlotinib as adjuvant therapy for patients with resected pancreatic cancer. First author DOI 10.1245/s10434-010-1401-9↗

Trials 2

  1. BPM31510 Administered Intravenously With Gemcitabine in Advanced Pancreatic Cancer Patients Principal investigator NCT02650804↗
  2. Gemcitabine+Nab-paclitaxel and FOLFIRINOX and Molecular Profiling for Patients With Advanced Pancreatic Cancer Principal investigator NCT01488552↗

Closest collaborators

The 25 strongest of 118 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Daniel D. Von Hoff · 17 shared papers, 2011–2020 · strength 0.94
  2. Elena Gabriela Chiorean · 6 shared papers, 2013–2020 · strength 0.37
  3. Daniel H. Ahn · 3 shared papers, 2017–2018 · strength 0.35
  4. David Goldstein · 5 shared papers, 2015–2020 · strength 0.32
  5. Mitesh J. Borad · 5 shared papers, 2011–2017 · strength 0.29
  6. Alok A. Khorana · 4 shared papers, 2014–2019 · strength 0.27
  7. Michael T. Barrett · 5 shared papers, 2012–2020 · strength 0.26
  8. Daniel A. Laheru · 5 shared papers, 2011–2020 · strength 0.25
  9. Philip A. Philip · 4 shared papers, 2014–2019 · strength 0.23
  10. Josep M. Tabernero · 4 shared papers, 2013–2020 · strength 0.22
  11. Ronald Lee Korn · 4 shared papers, 2011–2017 · strength 0.21
  12. Tanios Bekaii‐Saab · 2 shared papers, 2017–2018 · strength 0.21
  13. Gayle Jameson · 3 shared papers, 2017–2020 · strength 0.20
  14. Markus Frederic Renschler · 3 shared papers, 2013–2017 · strength 0.18
  15. Davendra P. S. Sohal · 3 shared papers, 2014–2018 · strength 0.18
  16. Volker Kunzmann · 3 shared papers, 2016–2017 · strength 0.18
  17. Michele Reni · 3 shared papers, 2013–2020 · strength 0.17
  18. N.V. Rajeshkumar · 3 shared papers, 2011–2020 · strength 0.17
  19. Anirban Maitra · 3 shared papers, 2011–2020 · strength 0.17
  20. Eileen Mary O'Reilly · 3 shared papers, 2015–2018 · strength 0.15
  21. Peter James O'Dwyer · 2 shared papers, 2017–2020 · strength 0.15
  22. Christopher H. Crane · 3 shared papers, 2011–2018 · strength 0.14
  23. Sunil R. Hingorani · 2 shared papers, 2015–2019 · strength 0.12
  24. Jeffrey R. Infante · 3 shared papers, 2013–2016 · strength 0.12
  25. Nathan Bahary · 4 shared papers, 2011–2015 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.